Immune therapy for hepatocellular carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Villanueva A, Hernandez-Gea V, Llovet JM. Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol 2013;10:34–42
Korangy F, Hochst B, Manns MP, et al. Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2010;4:345–353
Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754–1764
Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 2004;127:S232–S241
Shouval D, Ilan Y. Immunization against hepatitis B through adoptive transfer of immunity. Intervirology 1995;38:41–46
Shouval D, Adler R, Ilan Y. Adoptive transfer of immunity to hepatitis B virus in mice by bone marrow transplantation from immune donors. Hepatology 1993;17:955–959
Ilan Y, Nagler A, Adler R, et al. Adoptive transfer of immunity to hepatitis B virus after T cell-depleted allogeneic bone marrow transplantation. Hepatology 1993;18:246–252
Schumann A, Lindemann M, Valentin-Gamazo C, et al. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009;87:103–111
Ilan Y, Nagler A, Adler R, et al. Ablation of persistent hepatitis B by bone marrow transplantation from a hepatitis B-immune donor. Gastroenterology 1993;104:1818–1821
Lau GK, Suri D, Liang R, et al. Resolution of chronic hepatitis B and anti-HBs seroconversion in humans by adoptive transfer of immunity to hepatitis B core antigen. Gastroenterology 2002;122:614–624
Lau GK, Lok AS, Liang RH, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology 1997;25:1497–1501
Gotsman I, Beinart R, Alper R, et al. Induction of oral tolerance towards hepatitis B envelope antigens in a murine model. Antiviral Res 2000;48:17–26
Ilan Y. Immune downregulation leads to upregulation of an antiviral response: a lesson from the hepatitis B virus. Microbes Infect 2002;4:1317–1326
Israeli E, Safadi R, Melhem A, et al. Induction of oral immune regulation towards liver-extracted proteins for treatment of chronic HBV and HCV hepatitis: results of a phase I clinical trial. Liver Int 2004;24:295–307
Safadi R, Israeli E, Papo O, et al. Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol 2003;98:2505–2515
Ilan Y, Gabay E, Amit G, et al. Suppression of human hepatoma in mice through adoptive transfer of immunity to the hepatitis B surface antigen. J Hepatol 1997;27:170–175
Zhang Y, Li Q, Liu N, et al. Detection of MAGE-1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Hepatogastroenterology 2008;55:2200–2206
Hiroishi K, Eguchi J, Baba T, et al. Strong CD8(+) T-cell responses against tumor-associated antigens prolong the recurrence-free interval after tumor treatment in patients with hepatocellular carcinoma. J Gastroenterol 2010;45:451–458
Motohashi S, Nakayama T. Natural killer T cell-mediated immunotherapy for malignant diseases. Front Biosci 2009;1:108–116
Servet C, Zitvogel L, Hosmalin A. Dendritic cells in innate immune responses against HIV. Curr Mol Med 2002;2:739–756
Shibolet O, Alper R, Zlotogarov L, et al. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells. Int J Cancer 2003;106:236–243
Tada F, Abe M, Hirooka M, et al. Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol 2012;41:1601–1609
Margalit M, Shibolet O, Klein A, et al. Suppression of hepatocellular carcinoma by transplantation of ex vivo immune-modulated NKT lymphocytes. Int J Cancer 2005;115:443–449
Ohira M, Nishida S, Tryphonopoulos P, et al. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma. Cell Transplant 2012;21:1397–1406
Wang H, Dai J, Hou S, et al. Treatment of hepatocellular carcinoma with adenoviral vector-mediated Flt3 ligand gene therapy. Cancer Gene Ther 2005;12:769–777
Gotsman I, Alper R, Klein A, et al. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice. Cancer 2002;94:406–414
Shibolet O, Alper R, Zlotogarov L, et al. Suppression of hepatocellular carcinoma growth via oral immune regulation towards tumor-associated antigens is associated with increased NKT and CD8+ lymphocytes. Oncology 2004;66:323–330
Zigmond E, Preston S, Pappo O, et al. Beta-glucosylceramide: a novel method for enhancement of natural killer T lymphoycte plasticity in murine models of immune-mediated disorders. Gut 2007;56:82–89
Mizrahi M, Lalazar G, Ben Ya’acov A, et al. Beta-glycoglycosphingolipid-induced augmentation of the anti-HBV immune response is associated with altered CD8 and NKT lymphocyte distribution: a novel adjuvant for HBV vaccination. Vaccine 2008;26:2589–2595
Ascierto PA, Simeone E, Sznol M, et al. Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies. Semin Oncol 2010;37:508–516
Wang BJ, Bao JJ, Wang JZ, et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 2011;17:3322–3329
He L, Zhang G, He Y, et al. Blockade of B7-H1 with sPD-1 improves immunity against murine hepatocarcinoma. Anticancer Res 2005;25:3309–3313
Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691–2697